The DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
PTEN loss in the continuum of common cancers, rare syndromes and mouse models
Open accessAbstract
PTEN is among the most frequently inactivated tumour suppressor genes in sporadic cancer. PTEN has dual protein and lipid phosphatase activity, and its tumour suppressor activity is dependent on its lipid phosphatase activity, which negatively regulates the PI3K–AKT–mTOR pathway. Germline mutations in PTEN have been described in a variety of rare syndromes that are collectively known as the PTEN hamartoma tumour syndromes (PHTS). Cowden syndrome is the best-described syndrome within PHTS, with approximately 80% of patients having germline PTEN mutations. Patients with Cowden syndrome have an increased incidence of cancers of the breast, thyroid and endometrium, which correspond to sporadic tumour types that commonly exhibit somatic PTEN inactivation. Pten deletion in mice leads to Cowden syndrome-like phenotypes, and tissue-specific Pten deletion has provided clues to the role of PTEN mutation and loss in specific tumour types. Studying PTEN in the continuum of rare syndromes, common cancers and mouse models provides insight into the role of PTEN in tumorigenesis and will inform targeted drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,876
Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K. A., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., et al. (1997) · Nature Genetics · doi:10.1038/ng0497-356 · Cited by 2,741
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
Liaw, D., Marsh, D. J., Li, J., Dahia, P. L. M., Wang, S. I., Zheng, Z., Bose, S., Call, K. M., Tsou, H. C., Peacoke, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-64 · Cited by 2,091
Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · cited 1×
“For example, acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer and trastuzumab in ERBB2 -amplified breast cancer are associated with Pten loss and/or maintenance of AKT activatio”
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 1×
“Mouse models could be used to show whether re-expression of Pten in Pten -deficient tumours leads to tumour regression, as is the case for Trp53 -null lymphomas and sarcomas upon Trp53 re-expressio”
The PI3K‒PDK1 connection: more than just a road to PKB
Vanhaesebroeck, B., & Alessi, D. R. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3460561 · Cited by 1,644
Pten is essential for embryonic development and tumour suppression
Cristofano, A. D., Pesce, B., Cordon-Cardo, C., & Pandolfi, P. P. (1998) · Nature Genetics · doi:10.1038/1235 · Cited by 1,516
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J. M., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa063564 · Cited by 1,253
PTEN and the PI3-Kinase Pathway in Cancer
Chalhoub, N., & Baker, S. J. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092311 · Cited by 1,245
The PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,237
BrafV600E cooperates with Pten loss to induce metastatic melanoma
Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky Jr, W. E., You, M. J., DePinho, R. A., McMahon, M., & Bosenberg, M. (2009) · Nature Genetics · doi:10.1038/ng.356 · Cited by 1,189
Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells
Yilmaz, Ö. H., Valdez, R., Theisen, B. K., Guo, W., Ferguson, D. O., Wu, H., & Morrison, S. J. (2006) · Nature · doi:10.1038/nature04703 · Cited by 1,113
Wang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G. V., Li, G., Roy-Burman, P., Nelson, P. S., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00215-0 · Cited by 1,109
Crystal Structure of the PTEN Tumor Suppressor
Lee, J.-O., Yang, H., Georgescu, M.-M., Di Cristofano, A., Maehama, T., Shi, Y., Dixon, J. E., Pandolfi, P., & Pavletich, N. P. (1999) · Cell · doi:10.1016/s0092-8674(00)81663-3 · Cited by 1,014
Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis
Krueger, D. A., Care, M. M., Holland, K., Agricola, K., Tudor, C., Mangeshkar, P., Wilson, K. A., Byars, A., Sahmoud, T., & Franz, D. N. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001671 · Cited by 1,006
Gazdar, A. F. (2009) · Oncogene · doi:10.1038/onc.2009.198 · Cited by 991
Essential role for nuclear PTEN in maintaining chromosomal integrity
Shen, W. H., Balajee, A. S., Wang, J., Wu, H., Eng, C., Pandolfi, P. P., & Yin, Y. (2007) · Cell · doi:10.1016/j.cell.2006.11.042 · Cited by 979
ErbB receptors and signaling pathways in cancer
Hynes, N. E., & MacDonald, G. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.010 · Cited by 956
Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems
Podsypanina, K., Ellenson, L. H., Nemes, A., Gu, J., Tamura, M., Yamada, K. M., Cordon-Cardo, C., Catoretti, G., Fisher, P. E., & Parsons, R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1563 · Cited by 946
Hirai, H., Sootome, H., Nakatsuru, Y., Miyama, K., Taguchi, S., Tsujioka, K., Ueno, Y., Hatch, H., Majumder, P. K., Pan, B.-S., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1012 · Cited by 860
Suzuki, A., de la Pompa, J. L., Stambolic, V., Elia, A. J., Sasaki, T., Barrantes, I. D. B., Ho, A., Wakeham, A., ltie, A., Khoo, W., et al. (1998) · Current Biology · doi:10.1016/s0960-9822(07)00488-5 · Cited by 818
PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention
Zhang, J., Grindley, J. C., Yin, T., Jayasinghe, S., He, X. C., Ross, J. T., Haug, J. S., Rupp, D., Porter-Westpfahl, K. S., Wiedemann, L. M., et al. (2006) · Nature · doi:10.1038/nature04747 · Cited by 817
Chresta, C. M., Davies, B. R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S. E., Vincent, J. P., Ellston, R., Jones, D., Sini, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1751 · Cited by 812
Varambally, S., Yu, J., Laxman, B., Rhodes, D. R., Mehra, R., Tomlins, S. A., Shah, R. B., Chandran, U., Monzon, F. A., Becich, M. J., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.001 · Cited by 800
Groszer, M., Erickson, R., Scripture-Adams, D. D., Lesche, R., Trumpp, A., Zack, J. A., Kornblum, H. I., Liu, X., & Wu, H. (2001) · Science · doi:10.1126/science.1065518 · Cited by 798
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation
Zheng, H., Ying, H., Yan, H., Kimmelman, A. C., Hiller, D. J., Chen, A.-J., Perry, S. R., Tonon, G., Chu, G. C., Ding, Z., et al. (2008) · Nature · doi:10.1038/nature07443 · Cited by 767
Ubiquitination regulates PTEN nuclear import and tumor suppression
Trotman, L. C., Wang, X., Alimonti, A., Chen, Z., Teruya-Feldstein, J., Yang, H., Pavletich, N. P., Carver, B. S., Cordon-Cardo, C., Erdjument-Bromage, H., et al. (2007) · Cell · doi:10.1016/j.cell.2006.11.040 · Cited by 748
Tashiro, H., Blazes, M. S., Wu, R., Cho, K. R., Bose, S., Wang, S. I., Li, J., Parsons, R. E., & Ellenson, L. H. (1997) · PubMed · Cited by 701
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.
Cairns, P., Okami, K., Halachmi, S., Halachmi, N., Esteller, M., Herman, J. G., Jen, J., Isaacs, W. B., Bova, G. S., & Sidransky, D. (1997) · PubMed · Cited by 700
Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas
Horie, Y., Suzuki, A., Kataoka, E., Sasaki, T., Hamada, K., Sasaki, J., Mizuno, K., Hasegawa, G., Kishimoto, H., Iizuka, M., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420513 · Cited by 698
Pten Dose Dictates Cancer Progression in the Prostate
Trotman, L. C., Niki, M., Dotan, Z. A., Koutcher, J. A., Di Cristofano, A., Xiao, A., Khoo, A. S., Roy-Burman, P., Greenberg, N. M., Dyke, T. V., et al. (2003) · PLoS Biology · doi:10.1371/journal.pbio.0000059 · Cited by 676
Wu, X., Senechal, K., Neshat, M. S., Whang, Y. E., & Sawyers, C. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15587 · Cited by 674
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate
Carver, B. S., Tran, J., Gopalan, A., Chen, Z., Shaikh, S., Carracedo, A., Alimonti, A., Nardella, C., Varmeh, S., Scardino, P. T., et al. (2009) · Nature Genetics · doi:10.1038/ng.370 · Cited by 659
Marsh, D. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.3.507 · Cited by 653
Marsh, D. J., Kum, J. B., Lunetta, K. L., Bennett, M. J., Gorlin, R. J., Ahmed, S. F., Bodurtha, J., Crowe, C., Curtis, M. A., Dasouki, M., et al. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.8.1461 · Cited by 612
T Cell-Specific Loss of Pten Leads to Defects in Central and Peripheral Tolerance
Suzuki, A., Yamaguchi, M. T., Ohteki, T., Sasaki, T., Kaisho, T., Kimura, Y., Yoshida, R., Wakeham, A., Higuchi, T., Fukumoto, M., et al. (2001) · Immunity · doi:10.1016/s1074-7613(01)00134-0 · Cited by 589
Cowden's Disease: A Possible New Symptom Complex with Multiple System Involvement
LLOYD, K. M., & DENNIS, M. (1963) · Annals of Internal Medicine · doi:10.7326/0003-4819-58-1-136 · Cited by 580
Subtle variations in Pten dose determine cancer susceptibility
Alimonti, A., Carracedo, A., Clohessy, J. G., Trotman, L. C., Nardella, C., Egia, A., Salmena, L., Sampieri, K., Haveman, W. J., Brogi, E., et al. (2010) · Nature Genetics · doi:10.1038/ng.556 · Cited by 580
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/−mice
Podsypanina, K., Lee, R. T., Politis, C., Hennessy, I., Crane, A., Puc, J., Neshat, M., Wang, H., Yang, L., Gibbons, J., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171060098 · Cited by 569
Zhang, J.-G., Wang, J.-J., Zhao, F., Liu, Q., Jiang, K., & Yang, G.-H. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.02.074 · Cited by 563
Buonamici, S., Williams, J., Morrissey, M., Wang, A., Guo, R., Vattay, A., Hsiao, K., Yuan, J., Green, J., Ospina, B., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001599 · Cited by 562
(1997) · PubMed · Cited by 512
Backman, S. A., Stambolic, V., Suzuki, A., Haight, J., Elia, A., Pretorius, J., Tsao, M.-S., Shannon, P., Bolon, B., Ivy, G. O., et al. (2001) · Nature Genetics · doi:10.1038/ng782 · Cited by 508
PTEN/MMAC1 mutations in endometrial cancers.
Risinger, J. I., Hayes, A. K., Berchuck, A., & Barrett, J. C. (1997) · PubMed · Cited by 506
Sos, M. L., Koker, M., Weir, B. A., Heynck, S., Rabinovsky, R., Zander, T., Seeger, J. M., Weiss, J., Fischer, F., Frommolt, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4055 · Cited by 504 · cited 1×
“However, resistant tumours emerge through multiple mechanisms, one of which might be homozygous deletion of PTEN”
Pten in stromal fibroblasts suppresses mammary epithelial tumours
Trimboli, A. J., Cantemir-Stone, C. Z., Li, F., Wallace, J. A., Merchant, A., Creasap, N., Thompson, J. C., Caserta, E., Wang, H., Chong, J.-L., et al. (2009) · Nature · doi:10.1038/nature08486 · Cited by 500
Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse
Di Cristofano, A., De Acetis, M., Koff, A., Cordon-Cardo, C., & P Pandolfi, P. (2001) · Nature Genetics · doi:10.1038/84879 · Cited by 498
Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma.
Guldberg, P., Straten, P. T., Birck, A., Ahrenkiel, V., Kirkin, A. F., & Zeuthen, J. (1997) · PubMed · Cited by 480
Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease
Kwon, C.-H., Zhu, X., Zhang, J., Knoop, L. L., Tharp, R., Smeyne, R. J., Eberhart, C. G., Burger, P. C., & Baker, S. J. (2001) · Nature Genetics · doi:10.1038/ng781 · Cited by 478
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis
King, J. C., Xu, J., Wongvipat, J., Hieronymus, H., Carver, B. S., Leung, D. H., Taylor, B. S., Sander, C., Cardiff, R. D., Couto, S. S., et al. (2009) · Nature Genetics · doi:10.1038/ng.371 · Cited by 477
Easton, J. B., & Houghton, P. J. (2006) · Oncogene · doi:10.1038/sj.onc.1209886 · Cited by 459
Dissecting the role of mTOR: Lessons from mTOR inhibitors
Dowling, R. J. O., Topisirovic, I., Fonseca, B. D., & Sonenberg, N. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.12.001 · Cited by 454
Silva, A., Yunes, J. A., Cardoso, B. A., Martins, L. R., Jotta, P. Y., Abecasis, M., Nowill, A. E., Leslie, N. R., Cardoso, A. A., & Barata, J. T. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34616 · Cited by 443
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia
Gutierrez, A., Sanda, T., Grebliunaite, R., Carracedo, A., Salmena, L., Ahn, Y., Dahlberg, S., Neuberg, D., Moreau, L. A., Winter, S. S., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206722 · Cited by 437
Stiles, B., Wang, Y., Stahl, A., Bassilian, S., Lee, W. P., Kim, Y.-J., Sherwin, R., Devaskar, S., Lesche, R., Magnuson, M. A., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308617100 · Cited by 436
Huse, J. T., Brennan, C., Hambardzumyan, D., Wee, B., Pena, J., Rouhanifard, S. H., Sohn-Lee, C., le Sage, C., Agami, R., Tuschl, T., et al. (2009) · Genes & Development · doi:10.1101/gad.1777409 · Cited by 431
Hideshima, T., Catley, L., Yasui, H., Ishitsuka, K., Raje, N., Mitsiades, C., Podar, K., Munshi, N. C., Chauhan, D., Richardson, P. G., et al. (2006) · Blood · doi:10.1182/blood-2005-08-3434 · Cited by 422
mTOR signaling and drug development in cancer
Dancey, J. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.21 · Cited by 417
High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice.
Stambolic, V., Tsao, M., MacPherson, D. P., Suzuki, A., Chapman, W. B., & Mak, T. W. (2000) · PubMed · Cited by 414
Poliseno, L., Salmena, L., Riccardi, L., Fornari, A., Song, M. S., Hobbs, R. M., Sportoletti, P., Varmeh, S., Egia, A., Fedele, G., et al. (2010) · Science Signaling · doi:10.1126/scisignal.2000594 · Cited by 410
Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.
Soria, J., Lee, H., Lee, J. I., Luo, W., Issa, J. J., Kemp, B. L., Liu, D. D., Kurie, J. M., Mao, L., & Khuri, F. R. (2002) · PubMed · Cited by 406
Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice
Huang, X., Wullschleger, S., Shpiro, N., McGuire, V. A., Sakamoto, K., Woods, Y. L., Mcburnie, W., Fleming, S., & Alessi, D. R. (2008) · Biochemical Journal · doi:10.1042/bj20080557 · Cited by 396
Furnari, F. B., Huang, H., & Cavenee, W. K. (1998) · PubMed · Cited by 395
Nuclear PTEN Regulates the APC-CDH1 Tumor-Suppressive Complex in a Phosphatase-Independent Manner
Song, M. S., Carracedo, A., Salmena, L., Song, S. J., Egia, A., Malumbres, M., & Pandolfi, P. P. (2011) · Cell · doi:10.1016/j.cell.2010.12.020 · Cited by 376
PTEN hamartoma tumor syndrome: an overview
Hobert, J. A., & Eng, C. (2009) · Genetics in Medicine · doi:10.1097/gim.0b013e3181ac9aea · Cited by 366
The role of PTEN signaling perturbations in cancer and in targeted therapy
Keniry, M., & Parsons, R. (2008) · Oncogene · doi:10.1038/onc.2008.248 · Cited by 358
mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice
Guertin, D. A., Stevens, D. M., Saitoh, M., Kinkel, S., Crosby, K., Sheen, J.-H., Mullholland, D. J., Magnuson, M. A., Wu, H., & Sabatini, D. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.017 · Cited by 355
Saal, L. H., Gruvberger-Saal, S. K., Persson, C., Lövgren, K., Jumppanen, M., Staaf, J., Jönsson, G., Pires, M. M., Maurer, M., Holm, K., et al. (2008) · Nature Genetics · doi:10.1038/ng.2007.39 · Cited by 355
Inactivation of p53 and Pten promotes invasive bladder cancer
Puzio-Kuter, A. M., Castillo-Martin, M., Kinkade, C. W., Wang, X., Shen, T. H., Matos, T., Shen, M. M., Cordon-Cardo, C., & Abate-Shen, C. (2009) · Genes & Development · doi:10.1101/gad.1772909 · Cited by 329
Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors.
Dahia, P. L. M., Marsh, D. J., Zheng, Z., Zedenius, J., Komminoth, P., Frisk, T., Wallin, G., Parsons, R. E., Longy, M., Larsson, C., et al. (1997) · PubMed · Cited by 327
PTEN hamartoma tumor syndromes
Blumenthal, G. M., & Dennis, P. A. (2008) · European Journal of Human Genetics · doi:10.1038/ejhg.2008.162 · Cited by 327
Self-citationHaploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression
Kwabi-Addo, B., Giri, D., Schmidt, K., Podsypanina, K., Parsons, R., Greenberg, N., & Ittmann, M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201167798 · Cited by 323
The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region
Georgescu, M.-M., Kirsch, K. H., Akagi, T., Shishido, T., & Hanafusa, H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.10182 · Cited by 317
Wang, S., Garcia, A. J., Wu, M., Lawson, D. A., Witte, O. N., & Wu, H. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510652103 · Cited by 308
PTEN negatively regulates neural stem cell self-renewal by modulating G 0 -G 1 cell cycle entry
Groszer, M., Erickson, R., Scripture-Adams, D. D., Dougherty, J. D., Le Belle, J., Zack, J. A., Geschwind, D. H., Liu, X., Kornblum, H. I., & Wu, H. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509939103 · Cited by 306 · cited 1×
“Deletion was associated with an increase in neural stem cell”
Salvesen, H. B., MacDonald, N., Ryan, A., Jacobs, I. J., Lynch, E. D., Akslen, L. A., & Das, S. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010101)91:1<22::aid-ijc1002>3.0.co;2-s · Cited by 294
Pten constrains centroacinar cell expansion and malignant transformation in the pancreas
Stanger, B. Z., Stiles, B., Lauwers, G. Y., Bardeesy, N., Mendoza, M., Wang, Y., Greenwood, A., Cheng, K.-H., McLaughlin, M., Brown, D., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.07.015 · Cited by 294
Pérez-Tenorio, G., Alkhori, L., Olsson, B., Waltersson, M. A., Nordenskjöld, B., Rutqvist, L. E., Skoog, L., & Stål, O. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1609 · Cited by 292
The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis
Hamada, K., Sasaki, T., Koni, P. A., Natsui, M., Kishimoto, H., Sasaki, J., Yajima, N., Horie, Y., Hasegawa, G., Naito, M., et al. (2005) · Genes & Development · doi:10.1101/gad.1308805 · Cited by 287
PTEN, PIK3CA, p-AKT, and p-p70S6K Status
Esteva, F. J., Guo, H., Zhang, S., Santa-Maria, C., Stone, S., Lanchbury, J. S., Sahin, A. A., Hortobagyi, G. N., & Yu, D. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090885 · Cited by 285
Zhou, X.-P., Waite, K. A., Pilarski, R., Hampel, H., Fernandez, M. J., Bos, C., Dasouki, M., Feldman, G. L., Greenberg, L. A., Ivanovich, J., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/377109 · Cited by 285
Garlich, J. R., De, P., Dey, N., Su, J. D., Peng, X., Miller, A., Murali, R., Lu, Y., Mills, G. B., Kundra, V., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-0669 · Cited by 279
Epigenetic Silencing of the PTEN Gene in Melanoma
Mirmohammadsadegh, A., Marini, A., Nambiar, S., Hassan, M., Tannapfel, A., Ruzicka, T., & Hengge, U. R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0384 · Cited by 279
Stage-specific sensitivity to p53 restoration during lung cancer progression
Feldser, D. M., Kostova, K. K., Winslow, M. M., Taylor, S. E., Cashman, C., Whittaker, C. A., Sanchez-Rivera, F. J., Resnick, R., Bronson, R., Hemann, M. T., et al. (2010) · Nature · doi:10.1038/nature09535 · Cited by 273
Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland
Li, G., Robinson, G. W., Lesche, R., Martinez-Diaz, H., Jiang, Z., Rozengurt, N., Wagner, K.-U., Wu, D.-C., Lane, T. F., Liu, X., et al. (2002) · Development · doi:10.1242/dev.129.17.4159 · Cited by 272
Pten Deletion in Adult Neural Stem/Progenitor Cells Enhances Constitutive Neurogenesis
Gregorian, C., Nakashima, J., Le Belle, J., Ohab, J., Kim, R., Liu, A., Smith, K. B., Groszer, M., Garcia, A. D., Sofroniew, M. V., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3095-08.2009 · Cited by 272
Heald, B., Mester, J., Rybicki, L., Orloff, M. S., Burke, C. A., & Eng, C. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.06.061 · Cited by 271
Pten Haploinsufficiency Accelerates Formation of High-Grade Astrocytomas
Kwon, C.-H., Zhao, D., Chen, J., Alcantara, S., Li, Y., Burns, D. K., Mason, R. P., Lee, E. Y.-H. P., Wu, H., & Parada, L. F. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6867 · Cited by 270
Slomovitz, B. M., Lu, K. H., Johnston, T., Coleman, R. L., Munsell, M., Broaddus, R. R., Walker, C., Ramondetta, L. M., Burke, T. W., Gershenson, D. M., et al. (2010) · Cancer · doi:10.1002/cncr.25515 · Cited by 269
Perren, A., Komminoth, P., Saremaslani, P., Matter, C., Feurer, S., Lees, J. A., Heitz, P. U., & Eng, C. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64624-x · Cited by 266
Weng, L.-P. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.6.599 · Cited by 264
(1999) · PubMed · Cited by 258
O'Brien, C., Wallin, J. J., Sampath, D., GuhaThakurta, D., Savage, H., Punnoose, E. A., Guan, J., Berry, L., Prior, W. W., Amler, L. C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2828 · Cited by 255
PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors
Dedes, K. J., Wetterskog, D., Mendes-Pereira, A. M., Natrajan, R., Lambros, M. B., Geyer, F. C., Vatcheva, R., Savage, K., Mackay, A., Lord, C. J., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001538 · Cited by 255
Selective activation of p53-mediated tumour suppression in high-grade tumours
Junttila, M. R., Karnezis, A. N., Garcia, D., Madriles, F., Kortlever, R. M., Rostker, F., Brown Swigart, L., Pham, D. M., Seo, Y., Evan, G. I., et al. (2010) · Nature · doi:10.1038/nature09526 · Cited by 245
Marsit, C. J., Zheng, S., Aldape, K., Hinds, P. W., Nelson, H. H., Wiencke, J. K., & Kelsey, K. T. (2005) · Human Pathology · doi:10.1016/j.humpath.2005.05.006 · Cited by 243
The deficiency of Akt1 is sufficient to suppress tumor development in Pten +/− mice
Chen, M.-L., Xu, P.-Z., Peng, X., Chen, W. S., Guzman, G., Yang, X., Di Cristofano, A., Pandolfi, P. P., & Hay, N. (2006) · Genes & Development · doi:10.1101/gad.1395006 · Cited by 241
Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy
Yuan, R., Kay, A., Berg, W. J., & Lebwohl, D. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-45 · Cited by 240
Angelov, L., Doolittle, N. D., Kraemer, D. F., Siegal, T., Barnett, G. H., Peereboom, D. M., Stevens, G., McGregor, J., Jahnke, K., Lacy, C. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.3789 · Cited by 236
Tamguney, T., & Stokoe, D. (2007) · Journal of Cell Science · doi:10.1242/jcs.015230 · Cited by 234
Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias.
Maxwell, G. L., Risinger, J. I., Gumbs, C. E., Shaw, H., Bentley, R. C., Barrett, J. C., Berchuck, A., & Futreal, P. A. (1998) · PubMed · Cited by 231
Promoter Methylation and Silencing of PTEN in Gastric Carcinoma
Kang, Y.-H., Lee, H. S., & Kim, W. H. (2002) · Laboratory Investigation · doi:10.1038/labinvest.3780422 · Cited by 231
McEllin, B., Camacho, C. V., Mukherjee, B., Hahm, B., Tomimatsu, N., Bachoo, R. M., & Burma, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4295 · Cited by 231
PTEN Signaling pathways in glioblastoma
Koul, D. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.9.6954 · Cited by 228
Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases.
Abate-Shen, C. T., Banach-Petrosky, W. A., Sun, X., et al. (2003) · PubMed · Cited by 228
Akt inhibitors in clinical development for the treatment of cancer
Pal, S. K., Reckamp, K., Yu, H., & Figlin, R. A. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.520701 · Cited by 226
Conditional Loss of Uterine Pten Unfailingly and Rapidly Induces Endometrial Cancer in Mice
Daikoku, T., Hirota, Y., Tranguch, S., Joshi, A. R., DeMayo, F. J., Lydon, J. P., Ellenson, L. H., & Dey, S. K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1274 · Cited by 225
Promoter methylation of the PTEN gene is a common molecular change in breast cancer
García, J. M., Silva, J., Peña, C., Garcia, V., Rodríguez, R., Cruz, M. A., Cantos, B., Provencio, M., España, P., & Bonilla, F. (2004) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20062 · Cited by 224
Venkatesan, A. M., Dehnhardt, C. M., Delos Santos, E., Chen, Z., Dos Santos, O., Ayral-Kaloustian, S., Khafizova, G., Brooijmans, N., Mallon, R., Hollander, I., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901830p · Cited by 216
Xiao, A., Wu, H., Pandolfi, P. P., Louis, D. N., & Van Dyke, T. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00029-6 · Cited by 188
Zhou, X.-P., Loukola, A., Salovaara, R., Nystrom-Lahti, M., Peltomäki, P., de la Chapelle, A., Aaltonen, L. A., & Eng, C. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64200-9 · Cited by 185
Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers
Cairns, P., Evron, E., Okami, K., Halachmi, N., Esteller, M., Herman, J. G., Bose, S., Wang, S. I., Parsons, R., & Sidransky, D. (1998) · Oncogene · doi:10.1038/sj.onc.1201855 · Cited by 180
Mulholland, D. J., Xin, L., Morim, A., Lawson, D., Witte, O., & Wu, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4673 · Cited by 179
Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor.
Georgescu, M. M., Kirsch, K. H., Kaloudis, P., Yang, H., Pavletich, N. P., & Hanafusa, H. (2000) · PubMed · Cited by 176
PTEN Gene Alterations in Lymphoid Neoplasms
Sakai, A., Thieblemont, C., Wellmann, A., Jaffe, E. S., & Raffeld, M. (1998) · Blood · doi:10.1182/blood.v92.9.3410 · Cited by 174
Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice
You, M. J., Castrillón, D. H., Bastian, B. C., O’Hagan, R. C., Bosenberg, M., Parsons, R. E., Chin, L., & DePinho, R. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022632099 · Cited by 171
PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers
Yokomizo, A., Tindall, D. J., Drabkin, H., Gemmill, R., Franklin, W., Yang, P., Sugio, K., Smith, D. I., & Liu, W. (1998) · Oncogene · doi:10.1038/sj.onc.1201956 · Cited by 170
Yanagi, S., Kishimoto, H., Kawahara, K., Sasaki, T., Sasaki, M., Nishio, M., Yajima, N., Hamada, K., Horie, Y., Kubo, H., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31854 · Cited by 169
The Protein Phosphatase Activity of PTEN Regulates Src Family Kinases and Controls Glioma Migration
Dey, N., Crosswell, H. E., De, P., Parsons, R., Peng, Q., Su, J. D., & Durden, D. L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1182 · Cited by 168
Prasad, G., Sottero, T. L., Yang, X., Mueller, S., James, C. D., Weiss, W. A., Polley, M. Y., Ozawa, T., Berger, M. S., Aftab, D. T., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq193 · Cited by 165
Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma.
Kanamori, Y., Kigawa, J., Itamochi, H., Shimada, M., Takahashi, M., Kamazawa, S., Sato, S., Akeshima, R., & Terakawa, N. (2001) · PubMed · Cited by 165
PTEN Promoter Methylation in Sporadic Thyroid Carcinomas
Álvarez-Núñez, F., Bussaglia, E., Mauricio, D., Ybarra, J., Vilar, M., Lerma, E., de Leiva, A., & Matías‐Guiu, X. (2006) · Thyroid · doi:10.1089/thy.2006.16.17 · Cited by 164
Hypomorphic Mutation of PDK1 Suppresses Tumorigenesis in PTEN+/− Mice
Bayascas, J. R., Leslie, N. R., Parsons, R. E., Fleming, S., & Alessi, D. R. (2005) · Current Biology · doi:10.1016/j.cub.2005.08.066 · Cited by 158
Adey, N. B., Huang, L., Ormonde, P. A., Baumgard, M., Pero, R. S., Byreddy, D. V., Tavtigian, S. V., & Bartel, P. L. (2000) · PubMed · Cited by 158
Gustafson, S. L., Zbuk, K. M., Scacheri, C., & Eng, C. (2007) · Seminars in Oncology · doi:10.1053/j.seminoncol.2007.07.009 · Cited by 148
Inactivation of thePTEN/MMAC1/TEP1 gene in human lung cancers
Kohno, T., Takahashi, M., Manda, R., & Yokota, J. (1998) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199806)22:2<152::aid-gcc10>3.0.co;2-s · Cited by 147
Rapamycin treatment for a child with germline PTEN mutation
Marsh, D. J., Trahair, T. N., Martin, J. L., Chee, W. Y., Walker, J. L., Kirk, E. P., Baxter, R. C., & Marshall, G. M. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1112 · Cited by 143
Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome
Orloff, M. S., & Eng, C. (2008) · Oncogene · doi:10.1038/onc.2008.237 · Cited by 141
Mutation and Allelic Loss of the PTEN/MMAC1 gene in Primary and Metastatic Melanoma Biopsies
Birck, A., Ahrenkiel, V., Zeuthen, J., HOU-JENSEN, K., & Guldberg, P. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00877.x · Cited by 141
Stiles, B. L., Kuralwalla-Martinez, C., Guo, W., Gregorian, C., Wang, Y., Tian, J., Magnuson, M. A., & Wu, H. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.7.2772-2781.2006 · Cited by 131
Somatic mutations of thePTEN tumor suppressor gene in sporadic follicular thyroid tumors
Halachmi, N., Halachmi, S., Evron, E., Cairns, P., Okami, K., Saji, M., Westra, W. H., Zeiger, M. A., Jen, J., & Sidransky, D. (1998) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199811)23:3<239::aid-gcc5>3.0.co;2-2 · Cited by 129
Davidson, L., Maccario, H., Perera, N. M., Yang, X., Spinelli, L., Tibarewal, P., Glancy, B., Gray, A., Weijer, C. J., Downes, C. P., et al. (2009) · Oncogene · doi:10.1038/onc.2009.384 · Cited by 127
Scarisbrick, J. J., Woolford, A. J. ‐., Russell‐Jones, R., & Whittaker, S. J. (2000) · Blood · doi:10.1182/blood.v95.9.2937.009k15_2937_2942 · Cited by 125
Zheng, H., Ying, H., Yan, H., Kimmelman, A. C., Hiller, D. J., Chen, A.-J., Perry, S. R., Tonon, G., Chu, G. C., Ding, Z., et al. (2008) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2008.73.047 · Cited by 124
Marsh, V., Winton, D. J., Williams, G. T., Dubois, N. C., Trumpp, A., Sansom, O. J., & Clarke, A. R. (2008) · Nature Genetics · doi:10.1038/ng.256 · Cited by 122
PTEN/MMAC1 mutations in hepatocellular carcinomas
Yao, Y. J., Ping, X. L., Zhang, H., Chen, F. F., Lee, P. K., Ahsan, H., Chen, C., Lee, P., Peacocke, M., Santella, R. M., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202659 · Cited by 121
Increased PTEN expression due to transcriptional activation of PPARγ by Lovastatin and Rosiglitazone
Teresi, R. E., Shaiu, C., Chen, C., Chatterjee, K., Waite, K. A., & Eng, C. (2006) · International Journal of Cancer · doi:10.1002/ijc.21799 · Cited by 120
Iwanaga, K., Yang, Y., Raso, M. G., Ma, L., Hanna, A. E., Thilaganathan, N., Moghaddam, S. J., Evans, C. M., Li, H., Cai, W., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3117 · Cited by 119
Bardenstein, D. S., McLean, I. W., Nerney, J., & Boatwright, R. (1988) · Ophthalmology · doi:10.1016/s0161-6420(88)33066-6 · Cited by 118
PTEN is a tumor suppressor in CML stem cells and BCR-ABL–induced leukemias in mice
Peng, C., Chen, Y., Yang, Z., Zhang, H., Osterby, L., Rosmarin, A. G., & Li, S. (2009) · Blood · doi:10.1182/blood-2009-06-228130 · Cited by 117
Wei, Q., Clarke, L., Scheidenhelm, D. K., Qian, B., Tong, A., Sabha, N., Karim, Z., Bock, N. A., Reti, R., Swoboda, R., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0712 · Cited by 116
Post-translational regulation of PTEN
Wang, X., & Jiang, X. (2008) · Oncogene · doi:10.1038/onc.2008.242 · Cited by 113
Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas
Wang, Y., DiGiovanna, J. J., Stern, J. B., Hornyak, T. J., Raffeld, M. A., Khan, S. G., Oh, K., Hollander, M. C., Dennis, P. A., & Kraemer, K. H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812401106 · Cited by 111
Self-citationTsuruta, H., Kishimoto, H., Sasaki, T., Horie, Y., Natsui, M., Shibata, Y., Hamada, K., Yajima, N., Kawahara, K., Sasaki, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4627 · Cited by 109
Burris, H. A., Rodon, J. A., Sharma, S., Herbst, R. S., Tabernero, J. M., Infante, J. R., Silva, A. M. E., Demanse, D., Hackl, W., & Baselga, J. M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3005 · Cited by 109
Silencing of the PTEN tumor‐suppressor gene in anaplastic thyroid cancer
Frisk, T., Foukakis, T., Dwight, T., Lundberg, J., Höög, A., Wallin, G., Eng, C., Zedenius, J., & Larsson, C. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10098 · Cited by 107
Yeager, N., Klein–Szanto, A. J., Kimura, S., & Cristofano, A. D. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3524 · Cited by 106
Chiu, C. W., Nozawa, H., & Hanahan, D. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0198 · Cited by 104
Chemoprevention and Treatment of Experimental Cowden's Disease by mTOR Inhibition with Rapamycin
SQUARIZE, C. H., CASTILHO, R. M., & Gutkind, J. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0922 · Cited by 103
Genetic Background Controls Tumor Development in Pten -Deficient Mice
Freeman, D., Lesche, R., Kertesz, N. L., Wang, S., Li, G., Gao, J., Groszer, M., Martinez-Diaz, H., Rozengurt, N., THOMAS, G. V., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4143 · Cited by 102
Granville, C. A., Warfel, N. A., Tsurutani, J., Hollander, M. C., Robertson, M., Fox, S. D., Veenstra, T. D., Issaq, H. J., Linnoila, R. I., & Dennis, P. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2570 · Cited by 98
Self-citationPTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer
Guigon, C. J., Zhao, L., Willingham, M. C., & Cheng, S.-Y. (2008) · Oncogene · doi:10.1038/onc.2008.407 · Cited by 94
Identification of PTEN mutations in metastatic melanoma specimens
Çelebi, J. T., Shendrik, I., Silvers, D. N., & Peacocke, M. (2000) · Journal of Medical Genetics · doi:10.1136/jmg.37.9.653 · Cited by 90
PTEN Expression in Melanoma: Relationship with Patient Survival, Bcl-2 Expression, and Proliferation
Mikhail, M., Velazquez, E., Shapiro, R. L., Berman, R. S., Pavlick, A. C., Sorhaindo, L., Spira, J., Mir, C. M., Panageas, K. S., Polsky, D., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0397 · Cited by 89
Korsten, H., der Made, A. Z., Ma, X., van der Kwast, T., & Trapman, J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005662 · Cited by 86
Seager, C. M., Puzio‐Kuter, A. M., Patel, T., Jain, S., Cordon‐Cardo, C., Kiernan, J. M., & Abate-Shen, C. T. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0169 · Cited by 84
Distinct roles for PTEN in prevention of T cell lymphoma and autoimmunity in mice
Liu, X., Karnell, J. L., Yin, B., Zhang, R., Zhang, J., Li, P., Choi, Y., Maltzman, J. S., Pear, W. S., Bassing, C. H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42382 · Cited by 84
Mutational Profile of the PTEN Gene in Primary Human Astrocytic Tumors and Cultivated Xenografts
Schmidt, E., Ichimura, K., Goike, H. M., Moshref, A., Liu, L., & Collins, V. P. (1999) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199911000-00007 · Cited by 83
Methylation of PTEN as a Prognostic Factor in Malignant Melanoma of the Skin
Lahtz, C., Stranzenbach, R., Fiedler, E., Helmbold, P., & Dammann, R. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.226 · Cited by 83
Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice
Li, Y., Podsypanina, K., Liu, X., Crane, A., Tan, L. K., Parsons, R. E., & VARMUS, H. E. (2001) · BMC Molecular Biology · doi:10.1186/1471-2199-2-2 · Cited by 82
Namba, R., Young, L. J. T., Abbey, C. K., Kim, L., Damonte, P., Borowsky, A. D., Qi, J., Tepper, C. G., MacLeod, C. L., Cardiff, R. D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2170 · Cited by 81
Zhang, W., Zhu, J. J., Efferson, C. L., Ware, C., Tammam, J. G., Angagaw, M. H., Laskey, J., Bettano, K. A., Kasibhatla, S., Reilly, J. F., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4385 · Cited by 78
Schade, B., Rao, T., Dourdin, N., Lesurf, R., Hallett, M. T., Cardiff, R. D., & Muller, W. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.018937 · Cited by 77
Edelman, G. M., Bedell, C., Shapiro, G. I., Pandya, S. S., Kwak, E. L., Scheffold, C., Nguyen, L. T., Laird, A., Baselga, J. M., & Rodon, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3004 · Cited by 77
Zhou, X. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.4.445 · Cited by 76
Molecular analysis ofPTEN andMXI1 in primary bladder carcinoma
Wang, D. S., Rieger‐Christ, K., Latini, J. M., Moinzadeh, A., Stoffel, J. T., Pezza, J. A., Saini, K. S., Libertino, J. A., & Summerhayes, I. C. (2000) · International Journal of Cancer · Cited by 72
Alterations of the MMAC1/PTEN Gene in Lymphoid Malignancies
Grønbæk, K., Zeuthen, J., Guldberg, P., Ralfkiaer, E. M., & HOU-JENSEN, K. (1998) · Blood · doi:10.1182/blood.v91.11.4388 · Cited by 71
A Robust Immunohistochemical Assay for Detecting PTEN Expression in Human Tumors
Sangale, Z., Prass, C. E., Carlson, A., Tikishvili, E., DeGrado, J., Lanchbury, J. S. S., & Stone, S. (2010) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e3181f1da13 · Cited by 69
DNA Mismatch Repair Deficiency Accelerates Endometrial Tumorigenesis in Pten Heterozygous Mice
Wang, H., Douglas, W., Lia, M., Edelmann, W., Kucherlapati, R., Podsypanina, K., Parsons, R. E., & Ellenson, L. H. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62573-4 · Cited by 69
In Vitro and In Vivo Inhibition of Neuroblastoma Tumor Cell Growth by AKT Inhibitor Perifosine
Li, Z., Tan, F., Liewehr, D. J., Steinberg, S. M., & Thiele, C. J. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq125 · Cited by 69
Mallon, R. G., Hollander, I. J., Feldberg, L. R., Lucas, J., Soloveva, V., Venkatesan, A. M., Dehnhardt, C. M., Santos, E. D., Chen, Z., dos Santos, O., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0954 · Cited by 67
Wagner, A. J., Hoff, D., LoRusso, P. M., Tibes, R., Mazina, K. E., Ware, J. A., Yan, Y., Derynck, M. K., & Demetri, G. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3501 · Cited by 66
Qiao, X., Zhang, L.-Y., Gamper, A. M., Fujita, T., & Wan, Y. (2010) · Cell Cycle · doi:10.4161/cc.9.19.13585 · Cited by 65
Inoue-Narita, T., Hamada, K., Sasaki, T., Hatakeyama, S., Fujita, S., Kawahara, K., Sasaki, M., Kishimoto, H., Eguchi, S., Kojima, I., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0889 · Cited by 64
Tolcher, A. W., Yap, T. A., Fearen, I., Taylor, A., Carpenter, C., Brunetto, A. T., Beeram, M., Papadopoulos, K. P., Yan, L., & Bono, J. S. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3503 · Cited by 64
Inhibition of PI3K by PX-866 Prevents Transforming Growth Factor-α–Induced Pulmonary Fibrosis
Cras, T. D. L., Korfhagen, T. R., Davidson, C. R., Schmidt, S., Fenchel, M. C., Ikegami, M., Whitsett, J. A., & Hardie, W. D. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090123 · Cited by 63
Cowden syndrome: Report of a case with immunohistochemical analysis and review of the literature
Scheper, M. A., Nikitakis, N. G., Sarlani, E., Sauk, J. J., & Meiller, T. F. (2006) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/j.tripleo.2005.06.026 · Cited by 60
Hlobílková, A., Guldberg, P., Thullberg, M., Zeuthen, J., Lukas, J., & Bártek, J. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4867 · Cited by 58
Rahman, M. A., Kyriazanos, I. D., Ono, T., Yamanoi, A., Kohno, H., Tsuchiya, M., & Nagasue, N. (2002) · International Journal of Cancer · doi:10.1002/ijc.10458 · Cited by 58
Baselga, J. M., Jonge, M. J. D., Rodon, J. A., Burris, H. A., Birle, D. C., Buck, S. S. D., Demanse, D., Ru, Q. C., Goldbrunner, M., & Bendell, J. C. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3003 · Cited by 53
Diegel, C. R., Cho, K. R., El‐Naggar, A. K., Williams, B. O., & Lindvall, C. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1758 · Cited by 51
Braña, I., LoRusso, P. M., Baselga, J. M., Heath, E. I., Patnaik, A., Gendreau, S., Laird, A., & Papadopoulos, K. P. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3030 · Cited by 51
Xu, X., Ehdaie, B., Ohara, N., Yoshino, T., & Deng, C. (2009) · Oncogene · doi:10.1038/onc.2009.375 · Cited by 49
Targeting the mTOR Pathway Using Deforolimus in Cancer Therapy
Mahalingam, D., Sankhala, K. K., Mita, A. C., Giles, F. J., & Mita, M. M. (2009) · Future Oncology · doi:10.2217/fon.09.9 · Cited by 48
Engel, C., Versmold, B., Wappenschmidt, B., Simard, J., Easton, D. F., Peock, S., Cook, M., Oliver‐Williams, C., Frost, D., Mayes, R., et al. (2010) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0517 · Cited by 48
Rapamycin Inhibits Anal Carcinogenesis in Two Preclinical Animal Models
Stelzer, M. K., Pitot, H. C., Liem, A., Lee, D., Kennedy, G. D., & Lambert, P. F. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0228 · Cited by 48
Genetic interactions between Pten and p53 in radiation-induced lymphoma development
Mao, J., Wu, D., Pérez‐Losada, J., Nagase, H., Delrosario, R., & Balmain, A. (2003) · Oncogene · doi:10.1038/sj.onc.1207083 · Cited by 46
Milam, M. R., Celestino, J., Wu, W., Broaddus, R. R., Schmeler, K. M., Slomovitz, B. M., Soliman, P. T., Gershenson, D. M., Wang, H., Ellenson, L. H., et al. (2007) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2006.10.872 · Cited by 45
Blando, J. M., Portis, M. J., Benavides, F. J., Alexander, A., Mills, G. B., Dave, B., Conti, C. J., Kim, J., & Walker, C. L. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080055 · Cited by 45
Çen, O., & Longnecker, R. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0833 · Cited by 44
Furman, R. R., Byrd, J. C., Flinn, I. W., Coutre, S. E., Benson, D. M., Brown, J. R., Kahl, B. S., Wagner‐Johnston, N. D., Giese, N. A., & Yu, A. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3032 · Cited by 43
Cited by
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
The functions and regulation of the PTEN tumour suppressor
Song, M. S., Salmena, L., & Pandolfi, P. P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3330 · Cited by 1,926
Phosphoinositides: Tiny Lipids With Giant Impact on Cell Regulation
Balla, T. (2013) · Physiological Reviews · doi:10.1152/physrev.00028.2012 · Cited by 1,638
A compendium of mutational cancer driver genes
Martínez-Jiménez, F., Muiños, F., Sentís, I., Deu-Pons, J., Reyes-Salazar, I., Arnedo-Pac, C., Mularoni, L., Pich, O., Bonet, J., Kranas, H., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0290-x · Cited by 1,296
Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth
Zhang, L., Zhang, S., Yao, J., Lowery, F. J., Zhang, Q., Huang, W.-C., Li, P., Li, M., Wang, X., Zhang, C., et al. (2015) · Nature · doi:10.1038/nature15376 · Cited by 1,175
Metadata
- Authors
- Hollander, M. C., Blumenthal, G. M., & Dennis, P. A.
- Venue
- Nature Reviews Cancer
- Published
- 2011-03-24
- Volume
- 11
- Issue
- 4
- Pages
- 289-301
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1996222881
- Cited by
- 794
- References
- 210
- FWCI
- 5.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.